“We are initiating coverage of Inovio Pharmaceuticals, Inc. with a Buy rating and a 12-month price target of $1.50 per share. In our view, Inovio is a highly diversified developer of differentiated DNA-based vaccines, which could represent novel and highly effective ways to treat various inflammatory, oncology-focused and infectious disorders. Our price target is derived from a comparable universe-based valuation methodology, which forecasts a total enterprise value of roughly $250mm based on the average valuations of comparable companies in the infectious disease and oncology arenas.,” Aegis’ analyst wrote.
A number of other firms have also recently commented on INO. Analysts at Maxim Group initiated coverage on shares of Inovio Pharmaceuticals in a research note to investors on Thursday, January 31st. They set a buy rating and a $1.00 price target on the stock. Analysts at Piper Jaffray initiated coverage on shares of Inovio Pharmaceuticals in a research note to investors on Thursday, January 17th. They set an overweight rating and a $1.00 price target on the stock.
Shares of Inovio Pharmaceuticals opened at 0.5377 on Monday. Inovio Pharmaceuticals has a one year low of $0.38 and a one year high of $0.83. The stock’s 50-day moving average is currently $0.68. The company’s market cap is $74.9 million.
Inovio Pharmaceuticals, Inc., formerly Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of vaccines, called deoxyribonucleic acid (DNA) vaccines, focused on cancers and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.